Darek Sanford, MD
Cardiovascular Disease · Newport, KYNPI 1932442175
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,738 of the $8,070 with a category attached, or 83.5%. It is spread thinly across 25 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 414 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novartis$1K
- Boehringer Ingelheim$935
- Amgen$817
- E.r. Squibb & Sons, L.L.C.$745
- Pfizer$506
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,32816%
- Food & beverage$6,73884%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $1,846 |
| Novartis | 104 | $1,450 |
| Boehringer Ingelheim | 62 | $935 |
| Amgen | 65 | $817 |
| E.r. Squibb & Sons, L.L.C. | 64 | $745 |
| Pfizer | 38 | $506 |
| Abbott | 6 | $424 |
| AstraZeneca | 10 | $229 |
| Edwards Lifesciences | 2 | $209 |
| Johnson & Johnson | 11 | $187 |
| Medtronic | 1 | $128 |
| Esperion Therapeutics, Inc. | 6 | $111 |
| Merck | 5 | $77 |
| Novo Nordisk | 4 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $49 |
| Abiomed | 2 | $48 |
| Bridgebio Pharma, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $26 |
| Octapharma USA, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,216
- WATCHMAN Access System$302
- SAPIEN 3 Ultra RESILIA$204
- MitraClip$135
- FFRangio$128
- TRICLIP$117
How this compares
$8,070 in reported general payments places this provider in the 80th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 21 | $891,805 |
| EliquisApixaban | 574 | $564,180 |
| JardianceEmpagliflozin | 259 | $357,652 |
| VyndaqelTafamidis Meglumine | 15 | $352,825 |
| EntrestoSacubitril/Valsartan | 150 | $208,854 |
| Repatha SureclickEvolocumab | 182 | $170,581 |
| XareltoRivaroxaban | 100 | $110,691 |
| FarxigaDapagliflozin Propanediol | 82 | $102,825 |
| MounjaroTirzepatide | 23 | $21,479 |
| Praluent PenAlirocumab | 23 | $17,672 |
| Metoprolol Succinate | 662 | $7,250 |
| Rosuvastatin Calcium | 622 | $7,042 |
| Atorvastatin Calcium | 621 | $5,246 |
| Losartan Potassium | 260 | $2,364 |
| Amiodarone Hcl | 75 | $2,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $506 | $1,808,809610 claims |
| Boehringer IngelheimJardiance | $935 | $357,652259 claims |
| NovartisEntresto | $1,450 | $208,854150 claims |
| Johnson & JohnsonXarelto | $187 | $110,691100 claims |
| AstraZenecaFarxiga | $229 | $102,82582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Newport
- Robert ToltzisNewport$7K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.